title: A comprehensive behavioral evaluation in the lithium-pilocarpine model in rats: effects of carisbamate administration during status epilepticus.
abstract: OBJECTIVE
  Administration of carisbamate during status epilepticus (SE) prevents the occurrence of motor seizures in the lithium-pilocarpine model and leads in a subpopulation of rats to spike-and-wave discharges characteristic of absence epilepsy. Widespread neuroprotection accompanied this change in seizure expression. To assess whether these carisbamate-induced changes affected comorbidity, we used a large battery of behavioral tests in rats that had developed temporal lobe or absence-like seizures.
  
  
  METHODS
  Lithium-pilocarpine or saline was administered to 60 adult rats. Carisbamate (90 mg/kg) or diazepam and saline was given 1 h after SE onset, and repeated 8 h later and twice daily over 6 more days. Rats were video-monitored for 2 months. Subsequently, locomotor activity, anxiety, and various types of memory were assessed.
  
  
  RESULTS
  In rats with motor seizures, treated or not with carisbamate, all features of behavior were impaired compared to controls. Rats exhibiting absence-like seizures after carisbamate treatment behaved as controls in all paradigms tested along with widespread neuroprotection.
  
  
  CONCLUSIONS
  Carisbamate treatment leading to absence-like instead of temporal lobe seizures impressively prevented behavioral comorbidities reported by patients with epilepsy as the most disabling.
authors.affiliation: Faculty of Medicine, INSERM U 666, Strasbourg, France.
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Faure
authors.forename: Gladys
authors.initials: G
authors.lastname: Akimana
authors.forename: José E M
authors.initials: JE
authors.lastname: Carneiro
authors.forename: Brigitte
authors.initials: B
authors.lastname: Cosquer
authors.forename: Arielle
authors.initials: A
authors.lastname: Ferrandon
authors.forename: Karin
authors.initials: K
authors.lastname: Geiger
authors.forename: Estelle
authors.initials: E
authors.lastname: Koning
authors.forename: Lorène
authors.initials: L
authors.lastname: Penazzi
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Cassel
authors.forename: Astrid
authors.initials: A
authors.lastname: Nehlig
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000008:administration & dosage*; D014150:Antipsychotic Agents / Q000633:toxicity; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000473:pathology; D002219:Carbamates / Q000008:administration & dosage*; D002452:Cell Count; D004195:Disease Models, Animal; D008094:Lithium / Q000633:toxicity; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008568:Memory / Q000187:drug effects; D019599:Mossy Fibers, Hippocampal / Q000187:drug effects / Q000473:pathology; D018721:Muscarinic Agonists / Q000633:toxicity; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D010862:Pilocarpine / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D013226:Status Epilepticus / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D014796:Visual Perception / Q000187:drug effects
chemical_list: D000927:Anticonvulsants; D014150:Antipsychotic Agents; D002219:Carbamates; D018721:Muscarinic Agonists; C518914:S-2-O-carbamoyl-1-o-chlorophenyl-ethanol; D010862:Pilocarpine; D008094:Lithium; D010751:Phosphopyruvate Hydratase
keywords: Carisbamate; Learning and memory; Lithium-pilocarpine; Neuroprotection; Temporal lobe epilepsy